Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Rani Therapeutics Holdings (RANI) EBITDA Margin (2020 - 2025)

Historic EBITDA Margin for Rani Therapeutics Holdings (RANI) over the last 5 years, with Q1 2025 value amounting to 6984.3%.

  • Rani Therapeutics Holdings' EBITDA Margin changed N/A to 6984.3% in Q1 2025 from the same period last year, while for Sep 2025 it was 3727.75%, marking a year-over-year decrease of 77239700.0%. This contributed to the annual value of 5186.19% for FY2024, which is N/A changed from last year.
  • According to the latest figures from Q1 2025, Rani Therapeutics Holdings' EBITDA Margin is 6984.3%.
  • Rani Therapeutics Holdings' 5-year EBITDA Margin high stood at 1445.02% for Q2 2023, and its period low was 6984.3% during Q1 2025.
  • In the last 4 years, Rani Therapeutics Holdings' EBITDA Margin had a median value of 384.22% in 2023 and averaged 523.54%.
  • Per our database at Business Quant, Rani Therapeutics Holdings' EBITDA Margin skyrocketed by 53818700bps in 2021 and then plummeted by -24916300bps in 2024.
  • Rani Therapeutics Holdings' EBITDA Margin (Quarter) stood at 268.13% in 2021, then skyrocketed by 487bps to 1036.57% in 2023, then plummeted by -240bps to 1455.06% in 2024, then tumbled by -380bps to 6984.3% in 2025.
  • Its EBITDA Margin was 6984.3% in Q1 2025, compared to 1455.06% in Q4 2024 and 1036.57% in Q4 2023.